According to American Society for Radiation Oncology 2010 report approximately 75% of oncology patients opt for radiation therapy. The primary aim of radiation therapy is to irradiate the tumor cells, however the normal cells being exposed to the radiation therapy get damaged. Normal tissue cells are capable of self-repair but the repetitive damage reduces the reparation properties of normal cells. Factors that increase the risk and severity of skin reactions include high daily cumulative radiation doses, the type of beam utilized for irradiation, large treatment field, treatment to areas with skin folds and whether the radiation was given with chemotherapy.

For the purpose of this study, the various products studied includes topical, dressing and oral. Topical are further classified as (antibiotics, hydrophilic creams, corticosteroids and others). Dressing are categorized as (no string barrier films, honey impregnated gauze, hydrogel and hydrocolloid dressings, silicone coated dressings and others). 

The geographic segmentation of the global radiodermatitis market is performed for the regions North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global radiodermatitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global radiodermatitis market. The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc, Stratpharma AG and 3M Healthcare.

The radiodermatitis market is driven by factors such as rising prevalence of cancer with patients opting for radiation therapy, technological advancement in the drug formulation such as hydrocolloids and hydrogels which expedites healing with minimal pain. In addition, rising physician awareness regarding disease etiology and increasing online marketing with affordable sale and purchase options will propel the market penetration of treatments. In 2021, topical segment held the largest market share chiefly due to factors such as corticosteroids are considered as the gold standard for the treatment of radiodermatitis and hydrophilic creams minimizes the patients discomfort by providing moisture to the dry desquamation skin area.

Dressings will be the fastest growing segment throughout the forecast period 2023-2030 majorly due to factors such as rising prevalence of radiodermatitis, wide range of dressings available as per the degree of skin complication due to radiation therapy. The hydrocolloid and hydrogel dressings are finding huge applications as they are used for the management of moist desquamation in order to promote a moist environment for reepithelization. The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc., Stratpharma AG and 3M Healthcare.

North America will be the fastest-growing market for radiodermatitis throughout the forecast period 2023-2030. According to the American Cancer Society, in 2017, about 1,688,780 new cancer cases were diagnosed. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of cancer, first treatment preference to treat cancer is given to radiation therapy, and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the increasing prevalence of radiodermatitis and rising fashion trend has resulted in the demand for radiation therapy to enhance the aesthetic appeal of personal beauty and affordable reimbursement scenario.

Asia Pacific dominated the radiodermatitis market for the base year 2021 and the factors that are anticipated to propel the market growth are the increasing number of chronic health complications resulting into demand for radiation therapy, competitive market due to presence of existing major and evolving players engaged in the manufacturing and sale of radiodermatitis products in these regions, increasing disposable incomes and supportive regulatory environment for radiodermatitis products. Moreover, factors such as developing healthcare infrastructure, extensive collaborations undertaken by pharmaceutical giants to expand their product portfolio in the untapped markets of developing areas with unmet medical needs are going to fuel the rapid growth of radiodermatitis market in Latin America, and Middle East and Africa region in the near future.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Radiodermatitis market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Radiodermatitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Radiodermatitis market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Radiodermatitis market?
• Which is the largest regional market for Radiodermatitis market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Radiodermatitis market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Radiodermatitis market worldwide?